Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedThe webpage has updated its date references, adding new dates in March 2025 while removing older dates from January 2025.SummaryDifference0.4%
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check31 days agoNo Change Detected
- Check38 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
- Check45 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check52 days agoChange DetectedSignificant updates include the posting of results on January 20, 2025, and the introduction of new metrics for assessing PSA response and immunological parameters, while several previously listed metrics and submission dates have been removed.SummaryDifference6%
- Check60 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.